Dapagliflozin for Long COVID
(DALCO Trial)
Trial Summary
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, if you are on weight loss treatment with certain medications like liraglutide or semaglutide, you cannot participate in the trial.
What data supports the effectiveness of the drug Dapagliflozin for Long COVID?
Is dapagliflozin generally safe for humans?
How does the drug dapagliflozin differ from other treatments for Long COVID?
Dapagliflozin is unique because it is originally a diabetes medication that works by helping the kidneys remove sugar from the body through urine, which is different from other treatments that might focus on directly addressing symptoms of Long COVID. There are no standard treatments for Long COVID, making dapagliflozin's novel mechanism of action potentially beneficial in managing this condition.3581011
What is the purpose of this trial?
This is a randomized, placebo-controlled study. Patients with long COVID will be randomized to receive dapagliflozin or placebo for 12 months.
Eligibility Criteria
This trial is for individuals experiencing long-term symptoms after COVID-19, known as Long COVID Syndrome. Specific details about who can join are not provided, but typically participants would need to meet certain health criteria.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dapagliflozin or placebo daily for 12 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Dapagliflozin
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Heart Institute Research Corporation
Lead Sponsor